成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

  2. Cell Cycle/DNA Damage Vitamin D Related/Nuclear Receptor Metabolic Enzyme/Protease Neuronal Signaling Membrane Transporter/Ion Channel Autophagy Apoptosis
  3. PPAR TRP Channel Autophagy Ferroptosis Apoptosis
  4. Rosiglitazone

Rosiglitazone  (Synonyms: 羅格列酮; BRL 49653)

目錄號: HY-17386 純度: 99.94%
COA 產(chǎn)品使用指南 技術(shù)支持

Rosiglitazone (BRL 49653) 是一種具有口服活性的 PPARγ 選擇性激動劑 (EC50: 60 nM, Kd: 40 nM)。Rosiglitazone 是一種 TRPC5 激活劑 (EC50: 30 μM) 和 TRPM3 抑制劑。Rosiglitazone 可用于肥胖、糖尿病、衰老、卵巢癌的研究。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報，我們不為任何個人用途提供產(chǎn)品和服務(wù)

Rosiglitazone Chemical Structure

Rosiglitazone Chemical Structure

CAS No. : 122320-73-4

1.  客戶無需承擔(dān)相應(yīng)的運輸費用。

2.  同一機構(gòu)（單位）同一產(chǎn)品試用裝僅限申領(lǐng)一次，同一機構(gòu)（單位）一年內(nèi)

     可免費申領(lǐng)三個不同產(chǎn)品的試用裝。

3.  試用裝只面向終端客戶。

規(guī)格 價格 是否有貨 數(shù)量
10 mM * 1 mL in DMSO ￥660
In-stock
50 mg ￥600
In-stock
100 mg ￥1050
In-stock
200 mg ￥1800
In-stock
500 mg   詢價  
1 g   詢價  

* Please select Quantity before adding items.

Customer Review

MCE 顧客使用本產(chǎn)品發(fā)表的 104 篇科研文獻(xiàn)

WB
IF
Cell Viability Assay

    Rosiglitazone purchased from MCE. Usage Cited in: Carcinogenesis. 2023 Mar 31;bgad015.  [Abstract]

    Rosiglitazone (ROSI; 15, 30, 60, 120, 240 μM; 24 h) significantly inhibits the growth of NCI-H929 and OPM-2 cells.

    Rosiglitazone purchased from MCE. Usage Cited in: Eur J Pharmacol. 2019 Jan 15;843:134-144.  [Abstract]

    Protein levels of BACE1 and APP are measured by western blot assay in cerebral cortex of 12-month-old AD mice with different treatments (RSG and GW9662).

    Rosiglitazone purchased from MCE. Usage Cited in: Eur J Pharmacol. 2019 Jan 15;843:134-144.  [Abstract]

    Protein levels of sAPPα and sAPPβ are measured by western blot assay in cerebral cortex of 12-month-old AD mice with different treatments (RSG and GW9662).

    Rosiglitazone purchased from MCE. Usage Cited in: Eur J Pharmacol. 2019 Jan 15;843:134-144.  [Abstract]

    PPARγ level is determined by IF assay in 3×Tg-AD mice, 3×Tg-AD mice with RSG treatment, 3×Tg-AD-KO mice, 3×Tg-AD-KO mice with GW9662 stimulation.

    Rosiglitazone purchased from MCE. Usage Cited in: Free Radic Biol Med. 2018 Aug 21;126:259-268.  [Abstract]

    Laser confocal microscope is performed to measure MMP indicated with the ratio of JC-1 Red/JC-1 Green. Nuclei are counterstained with DAPI (blue). Bar graphs represent the mean ± SD of red/green fluorescence intensity.

    Rosiglitazone purchased from MCE. Usage Cited in: Front Mol Neurosci. 2017 Sep 14;10:293.  [Abstract]

    Rosiglitazone enhances the phosphorylation of insulin receptor substrate 1 (IRS1, phosphorylated at Ser 636/639), which is considered to be the main activator of the Akt/mTOR pathway by IGF-1R.

    查看 PPAR 亞型特異性產(chǎn)品:

    查看 TRP Channel 亞型特異性產(chǎn)品:

    • 生物活性

    • 純度 & 產(chǎn)品資料

    • 參考文獻(xiàn)

    生物活性

    Rosiglitazone (BRL 49653) is an orally active selective PPARγ agonist (EC50: 60 nM, Kd: 40 nM). Rosiglitazone is an TRPC5 activator (EC50: 30 μM) and TRPM3 inhibitor. Rosiglitazone can be used in the research of obesity and diabetes, senescence, ovarian cancer[1][2][4][7].

    IC50 & Target[1][2][4]

    PPARγ

    40 nM (Kd)

    PPARγ

    60 nM (EC50)

    TRPC5

    30 μM (EC50)

    TRPM3

     

    細(xì)胞效力
    (Cellular Effect)
    Cell Line Type Value Description References
    3T3-L1 EC50
    0.12 μM
    Compound: Rosiglitazone
    Antidiabetic activity in mouse 3T3L1 preadipocytes assessed as increase in triglycerides level after 6 days
    Antidiabetic activity in mouse 3T3L1 preadipocytes assessed as increase in triglycerides level after 6 days
    		[PMID: 32130008]
    3T3-L1 EC50
    1.72 μM
    Compound: 1; Rosi
    Induction of insulin-stimulated 2-NBDG uptake in TNF-alpha-induced insulin resistant mouse 3T3L1 cells preincubated for 48 hrs followed by 2-NBDG addition measured after 30 mins in presence of insulin by fluorescence assay
    Induction of insulin-stimulated 2-NBDG uptake in TNF-alpha-induced insulin resistant mouse 3T3L1 cells preincubated for 48 hrs followed by 2-NBDG addition measured after 30 mins in presence of insulin by fluorescence assay
    		[PMID: 30481687]
    BHK-21 EC50
    0.45 μM
    Compound: RSG
    Agonist activity at human PPARgamma expressed in BHK21 cells assessed as SEAP activity by luciferase reporter transactivation assay
    Agonist activity at human PPARgamma expressed in BHK21 cells assessed as SEAP activity by luciferase reporter transactivation assay
    		[PMID: 19349176]
    CHO IC50
    29.5 μM
    Compound: 1; Rosi
    Inhibition of human ERG expressed in CHO cells by patch clamp assay
    Inhibition of human ERG expressed in CHO cells by patch clamp assay
    		[PMID: 30481687]
    CHO-K1 EC50
    0.1 μM
    Compound: Rosiglitazone
    Partial agonist activity at human PPARgamma-LBD expressed in CHO-K1 cells co-transfected with GAL4 assessed as luciferase activity by transactivation assay
    Partial agonist activity at human PPARgamma-LBD expressed in CHO-K1 cells co-transfected with GAL4 assessed as luciferase activity by transactivation assay
    		[PMID: 20527969]
    COS-1 EC50
    > 1000 nM
    Compound: BRL
    Agonist activity at human PPARalpha ligand binding domain expressed in COS-1 cells co-transfected with Gal4 after 24 hrs by luciferase reporter gene assay
    Agonist activity at human PPARalpha ligand binding domain expressed in COS-1 cells co-transfected with Gal4 after 24 hrs by luciferase reporter gene assay
    		[PMID: 22051054]
    COS-1 EC50
    > 1000 nM
    Compound: BRL
    Agonist activity at human PPARdelta ligand binding domain expressed in COS-1 cells after 24 hrs by luciferase reporter gene-based luminometric analysis
    Agonist activity at human PPARdelta ligand binding domain expressed in COS-1 cells after 24 hrs by luciferase reporter gene-based luminometric analysis
    		[PMID: 22051054]
    COS-1 EC50
    > 3000 nM
    Compound: Rosiglitazone
    Agonist activity at human PPARalpha receptor expressed in african green monkey COS1 cells co-transfected with fused yeast Gal4-DBD by transactivation assay
    Agonist activity at human PPARalpha receptor expressed in african green monkey COS1 cells co-transfected with fused yeast Gal4-DBD by transactivation assay
    		[PMID: 19530681]
    COS-1 EC50
    > 3000 nM
    Compound: Rosiglitazone
    Agonist activity at mouse PPARalpha receptor expressed in african green monkey COS1 cells co-transfected with fused yeast Gal4-DBD by transactivation assay
    Agonist activity at mouse PPARalpha receptor expressed in african green monkey COS1 cells co-transfected with fused yeast Gal4-DBD by transactivation assay
    		[PMID: 19530681]
    COS-1 EC50
    0.12 μM
    Compound: Rosiglitazone
    Transactivation of human full length PPARgamma expressed in COS1 cells co-transfected with RXRalpha after 24 hrs by luciferase reporter gene assay
    Transactivation of human full length PPARgamma expressed in COS1 cells co-transfected with RXRalpha after 24 hrs by luciferase reporter gene assay
    		[PMID: 22197396]
    COS-1 EC50
    20 nM
    Compound: rosiglitazone
    Agonist activity at human recombinant PPARgamma expressed in COS1 cells co-expressing GAL4 assessed as transcriptional activity after 48 hrs by luciferase reporter gene assay
    Agonist activity at human recombinant PPARgamma expressed in COS1 cells co-expressing GAL4 assessed as transcriptional activity after 48 hrs by luciferase reporter gene assay
    		[PMID: 19507861]
    COS-1 EC50
    20 nM
    Compound: Rosiglitazone
    Agonist activity at human PPARgamma receptor expressed in african green monkey COS1 cells co-transfected with fused yeast Gal4-DBD by transactivation assay
    Agonist activity at human PPARgamma receptor expressed in african green monkey COS1 cells co-transfected with fused yeast Gal4-DBD by transactivation assay
    		[PMID: 19530681]
    COS-1 EC50
    48 nM
    Compound: BRL
    Agonist activity at human PPARgamma ligand binding domain expressed in COS-1 cells after 24 hrs by luciferase reporter gene-based luminometric analysis
    Agonist activity at human PPARgamma ligand binding domain expressed in COS-1 cells after 24 hrs by luciferase reporter gene-based luminometric analysis
    		[PMID: 22051054]
    COS-7 EC50
    > 10 μM
    Compound: 4
    Agonist activity at human recombinant PPARalpha LBD expressed in african green monkey COS7 cells coexpressing GAL4 by luciferase reporter gene transactivation assay
    Agonist activity at human recombinant PPARalpha LBD expressed in african green monkey COS7 cells coexpressing GAL4 by luciferase reporter gene transactivation assay
    		[PMID: 20138762]
    COS-7 EC50
    0.03 μM
    Compound: 4
    Agonist activity at human recombinant PPARgamma1 LBD expressed in african green monkey COS7 cells coexpressing GAL4 by luciferase reporter gene transactivation assay
    Agonist activity at human recombinant PPARgamma1 LBD expressed in african green monkey COS7 cells coexpressing GAL4 by luciferase reporter gene transactivation assay
    		[PMID: 20138762]
    COS-7 EC50
    0.043 μM
    Compound: Rosiglitazone
    Modulation of human PPARgamma-LBD expressed in african green monkey COS7 cells co-transfected with Gal4 assessed as activation of transactivation activity by luciferase assay
    Modulation of human PPARgamma-LBD expressed in african green monkey COS7 cells co-transfected with Gal4 assessed as activation of transactivation activity by luciferase assay
    		[PMID: 21873070]
    COS-7 EC50
    0.1 μM
    Compound: 4
    Agonist activity at human recombinant PPARgamma2 LBD expressed in african green monkey COS7 cells coexpressing GAL4 by luciferase reporter gene transactivation assay
    Agonist activity at human recombinant PPARgamma2 LBD expressed in african green monkey COS7 cells coexpressing GAL4 by luciferase reporter gene transactivation assay
    		[PMID: 20138762]
    CV-1 EC50
    > 10 μM
    Compound: Rosiglitazone
    Agonist activity at human PPARalpha-LBD expressed in CV1 cells co-transfected with Gal4 after 40 hrs by luciferase based transactivation assay
    Agonist activity at human PPARalpha-LBD expressed in CV1 cells co-transfected with Gal4 after 40 hrs by luciferase based transactivation assay
    		[PMID: 21515063]
    CV-1 EC50
    > 10 μM
    Compound: Rosiglitazone
    Agonist activity at human PPARdelta-LBD expressed in CV1 cells co-transfected with Gal4 after 40 hrs by luciferase based transactivation assay
    Agonist activity at human PPARdelta-LBD expressed in CV1 cells co-transfected with Gal4 after 40 hrs by luciferase based transactivation assay
    		[PMID: 21515063]
    CV-1 EC50
    > 10 μM
    Compound: Rosiglitazone
    Transactivation of Gal4-fused human PPARalpha DNA binding domain expressed in african green monkey CV1 cells by luciferase reporter gene assay
    Transactivation of Gal4-fused human PPARalpha DNA binding domain expressed in african green monkey CV1 cells by luciferase reporter gene assay
    		[PMID: 21112784]
    CV-1 EC50
    > 10 μM
    Compound: Rosiglitazone
    Transactivation of Gal4-fused human PPARdelta DNA binding domain expressed in african green monkey CV1 cells by luciferase reporter gene assay
    Transactivation of Gal4-fused human PPARdelta DNA binding domain expressed in african green monkey CV1 cells by luciferase reporter gene assay
    		[PMID: 21112784]
    CV-1 EC50
    0.03 μM
    Compound: rosiglitazone
    Agonist activity at human PPARgamma in CV1 cells by GAL4 transactivation assay after 24 hrs
    Agonist activity at human PPARgamma in CV1 cells by GAL4 transactivation assay after 24 hrs
    		[PMID: 17507225]
    CV-1 EC50
    0.033 μM
    Compound: rosiglitazone
    Agonist activity at human PPARgamma ligand binding domain expressed in african green monkey CV1 cells co-transfected with fused Gal4-DBD by transactivation assay
    Agonist activity at human PPARgamma ligand binding domain expressed in african green monkey CV1 cells co-transfected with fused Gal4-DBD by transactivation assay
    		[PMID: 18826205]
    CV-1 EC50
    0.1 μM
    Compound: Rosiglitazone
    Agonist activity at human PPARgamma-LBD expressed in CV1 cells co-transfected with Gal4 after 40 hrs by luciferase based transactivation assay
    Agonist activity at human PPARgamma-LBD expressed in CV1 cells co-transfected with Gal4 after 40 hrs by luciferase based transactivation assay
    		[PMID: 21515063]
    CV-1 EC50
    0.1 μM
    Compound: Rosiglitazone
    Transactivation of Gal4-fused human PPARgamma DNA binding domain expressed in african green monkey CV1 cells by luciferase reporter gene assay
    Transactivation of Gal4-fused human PPARgamma DNA binding domain expressed in african green monkey CV1 cells by luciferase reporter gene assay
    		[PMID: 21112784]
    CV-1 EC50
    3.46 μM
    Compound: rosiglitazone
    Agonist activity at human PPARalpha in CV1 cells by GAL4 transactivation assay after 24 hrs
    Agonist activity at human PPARalpha in CV1 cells by GAL4 transactivation assay after 24 hrs
    		[PMID: 17507225]
    CV-1 EC50
    3.46 μM
    Compound: rosiglitazone
    Agonist activity at human PPARalpha ligand binding domain expressed in african green monkey CV1 cells co-transfected with fused Gal4-DBD by transactivation assay
    Agonist activity at human PPARalpha ligand binding domain expressed in african green monkey CV1 cells co-transfected with fused Gal4-DBD by transactivation assay
    		[PMID: 18826205]
    CV-1 EC50
    308 nM
    Compound: rosiglitazone
    Agonist activity at human PPARgamma expressed in CV1 cells by receptor transactivation assay
    Agonist activity at human PPARgamma expressed in CV1 cells by receptor transactivation assay
    		[PMID: 18029178]
    CV-1 EC50
    308 nM
    Compound: rosiglitazone
    Agonist activity at PPARgamma in CV1 cells by transactivation assay
    Agonist activity at PPARgamma in CV1 cells by transactivation assay
    		[PMID: 17129725]
    CV-1 EC50
    308 nM
    Compound: Rosiglitazone
    Transactivation of human PPARgamma in CV1 cells by luciferase reporter gene assay
    Transactivation of human PPARgamma in CV1 cells by luciferase reporter gene assay
    		[PMID: 16970391]
    CV-1 EC50
    325 nM
    Compound: BRL-49653, rosiglitazone
    In vitro evaluation against RXR-alpha/PPAR-gamma in CV-1 cells by cotransfection assay was determined
    In vitro evaluation against RXR-alpha/PPAR-gamma in CV-1 cells by cotransfection assay was determined
    		[PMID: 12954061]
    CV-1 EC50
    43 nM
    Compound: Rosiglitazone
    Maximal reporter activity against human Peroxisome proliferator activated receptor gamma Gal4 chimeric in transiently transfected CV-1 cells by functional assay.
    Maximal reporter activity against human Peroxisome proliferator activated receptor gamma Gal4 chimeric in transiently transfected CV-1 cells by functional assay.
    		[PMID: 11720854]
    DU-145 IC50
    16 μM
    Compound: Rosiglitazone
    Cytotoxicity against human DU145 cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human DU145 cells assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 24996143]
    HEK293 EC50
    > 10 μM
    Compound: rosiglitazone
    Activity at human liver PPAR alpha expressed in HEK293 cells by PPAR-GAL4 transactivation assay
    Activity at human liver PPAR alpha expressed in HEK293 cells by PPAR-GAL4 transactivation assay
    		[PMID: 17343371]
    HEK293 EC50
    > 5 μM
    Compound: rosiglitazone
    Agonist activity at PPARalpha in HEK293 cells by GAL4 transactivation assay
    Agonist activity at PPARalpha in HEK293 cells by GAL4 transactivation assay
    		[PMID: 18291645]
    HEK293 EC50
    0.004 μM
    Compound: Rosiglitazone
    Agonist at human PPARgamma LBD expressed in human HEK293 cells cotransfected with GAL4-Luc assessed as transcriptional activation by luciferase reporter gene assay
    Agonist at human PPARgamma LBD expressed in human HEK293 cells cotransfected with GAL4-Luc assessed as transcriptional activation by luciferase reporter gene assay
    		[PMID: 23286787]
    HEK293 EC50
    0.03 μM
    Compound: rosiglitazone
    Agonist activity at mouse PPARgamma expressed in HEK293 cells co-expressing with Gal4 reporter vector after 24 hrs by dual-luciferase reporter assay
    Agonist activity at mouse PPARgamma expressed in HEK293 cells co-expressing with Gal4 reporter vector after 24 hrs by dual-luciferase reporter assay
    		[PMID: 24955889]
    HEK293 EC50
    0.035 μM
    Compound: Rosiglitazone
    Agonist activity at human GAL4-tagged PPARgamma chimeric receptor expressed in HEK cells by transactivation assay
    Agonist activity at human GAL4-tagged PPARgamma chimeric receptor expressed in HEK cells by transactivation assay
    		[PMID: 20299214]
    HEK293 EC50
    0.035 μM
    Compound: rosiglitazone
    Agonist activity at PPARgamma receptor expressed in HEK293 cells by GAL4 transactivation assay
    Agonist activity at PPARgamma receptor expressed in HEK293 cells by GAL4 transactivation assay
    		[PMID: 17292606]
    HEK293 EC50
    0.039 μM
    Compound: Rosiglitazone
    Transactivation of human PPARgamma expressed in HEK293 cells incubated for 18 hrs by dual luciferase reporter gene assay
    Transactivation of human PPARgamma expressed in HEK293 cells incubated for 18 hrs by dual luciferase reporter gene assay
    		10.1039/C5MD00151J
    HEK293 EC50
    0.045 μM
    Compound: rosiglitazone
    Agonist activity at PPARgamma in HEK293 cells by GAL4 transactivation assay
    Agonist activity at PPARgamma in HEK293 cells by GAL4 transactivation assay
    		[PMID: 18291645]
    HEK293 EC50
    0.1 μM
    Compound: 1, Avandia
    Transactivation of GAL4 DBD-fused human PPARgamma-LBD expressed in HEK293 cells after 24 hrs by luciferase reporter gene assay
    Transactivation of GAL4 DBD-fused human PPARgamma-LBD expressed in HEK293 cells after 24 hrs by luciferase reporter gene assay
    		[PMID: 23294830]
    HEK293 EC50
    0.19 μM
    Compound: Rosiglitazone
    Agonist activity at PPARgamma expressed in HEK293 cells by GAL4 transactivation assay
    Agonist activity at PPARgamma expressed in HEK293 cells by GAL4 transactivation assay
    		[PMID: 18029176]
    HEK293 EC50
    0.26 μM
    Compound: Rosiglitazone
    Agonist activity at N-terminal Gal4 fused human PPARgamma LBD transfected in HEK293 cells after 24 hrs by luciferase reporter gene assay
    Agonist activity at N-terminal Gal4 fused human PPARgamma LBD transfected in HEK293 cells after 24 hrs by luciferase reporter gene assay
    		[PMID: 27622746]
    HEK293 EC50
    0.26 μM
    Compound: Rosiglitazone
    Agonist activity at GAL4-tagged human PPARgamma ligand binding domain chimeric receptor expressed in HEK293 cells after 24 hrs by luciferase reporter gene assay
    Agonist activity at GAL4-tagged human PPARgamma ligand binding domain chimeric receptor expressed in HEK293 cells after 24 hrs by luciferase reporter gene assay
    		[PMID: 27591006]
    HEK293 EC50
    0.3 μM
    Compound: Rosiglitazone
    Agonist activity at GAL4N fused human PPARgamma LBD expressed in HEK293 cells co-expressing TK-MH100x4-Luc after 24 hrs by luciferase reporter gene assay
    Agonist activity at GAL4N fused human PPARgamma LBD expressed in HEK293 cells co-expressing TK-MH100x4-Luc after 24 hrs by luciferase reporter gene assay
    		[PMID: 28539218]
    HEK293 EC50
    0.31 μM
    Compound: rosiglitazone
    Activity at human adipose tissue PPAR gamma expressed in HEK293 cells by PPAR-GAL4 transactivation assay
    Activity at human adipose tissue PPAR gamma expressed in HEK293 cells by PPAR-GAL4 transactivation assay
    		[PMID: 17343371]
    HEK293 EC50
    1.1 μM
    Compound: 2
    Transactivation activity at Gal4 fused full length human PPARgamma LBD expressed in HEK293 cells after 24 hrs by luciferase reporter gene assay
    Transactivation activity at Gal4 fused full length human PPARgamma LBD expressed in HEK293 cells after 24 hrs by luciferase reporter gene assay
    		[PMID: 28465099]
    HEK293 EC50
    10 nM
    Compound: RGZ
    Agonist activity at human PPARgamma expressed in HEK293 cells by luciferase reporter gene assay
    Agonist activity at human PPARgamma expressed in HEK293 cells by luciferase reporter gene assay
    		[PMID: 25305688]
    HEK293 EC50
    10.58 μM
    Compound: Rosiglitazone
    Agonist activity at human GAL4-tagged PPARalpha chimeric receptor expressed in HEK cells by transactivation assay
    Agonist activity at human GAL4-tagged PPARalpha chimeric receptor expressed in HEK cells by transactivation assay
    		[PMID: 20299214]
    HEK293 IC50
    22 μM
    Compound: 2
    Transrepression activity at human PPARgamma expressed in HEK293 cells assessed as inhibition of TNFalpha induced NF-kappaB promoter activity pretreated for 4 hrs followed by TNFalpha stimulation after 3 hrs by luciferase reporter gene assay
    Transrepression activity at human PPARgamma expressed in HEK293 cells assessed as inhibition of TNFalpha induced NF-kappaB promoter activity pretreated for 4 hrs followed by TNFalpha stimulation after 3 hrs by luciferase reporter gene assay
    		[PMID: 28465099]
    HEK293 EC50
    43 nM
    Compound: Rosiglitazone
    Transactivation of Gal4-fused human PPARgamma expressed in HEK293 cells after 16 to 20 hrs by luciferase reporter gene assay
    Transactivation of Gal4-fused human PPARgamma expressed in HEK293 cells after 16 to 20 hrs by luciferase reporter gene assay
    		[PMID: 21128600]
    HEK293 EC50
    43.71 μM
    Compound: Rosiglitazone
    Agonist activity at human PPARgamma expressed in HEK293 cells cotransfected with PPREx4-TK-luc assessed as activation of luciferase activity measured after 48 hrs by transactivation assay
    Agonist activity at human PPARgamma expressed in HEK293 cells cotransfected with PPREx4-TK-luc assessed as activation of luciferase activity measured after 48 hrs by transactivation assay
    		[PMID: 23265844]
    HeLa EC50
    > 10000 nM
    Compound: 1
    Agonist activity at PPARalpha ligand binding domain expressed in human HeLa cells co-transfected with Gal4-DBD assessed as transcriptional activation by Gal4 response element-driven luciferase reporter gene assay
    Agonist activity at PPARalpha ligand binding domain expressed in human HeLa cells co-transfected with Gal4-DBD assessed as transcriptional activation by Gal4 response element-driven luciferase reporter gene assay
    		[PMID: 19275963]
    HeLa EC50
    > 10000 nM
    Compound: 1
    Agonist activity at PPARdelta ligand binding domain expressed in human HeLa cells co-transfected with Gal4-DBD assessed as transcriptional activation by Gal4 response element-driven luciferase reporter gene assay
    Agonist activity at PPARdelta ligand binding domain expressed in human HeLa cells co-transfected with Gal4-DBD assessed as transcriptional activation by Gal4 response element-driven luciferase reporter gene assay
    		[PMID: 19275963]
    HeLa EC50
    15 nM
    Compound: 1
    Agonist activity at PPARgamma ligand binding domain expressed in human HeLa cells co-transfected with Gal4-DBD assessed as transcriptional activation by Gal4 response element-driven luciferase reporter gene assay
    Agonist activity at PPARgamma ligand binding domain expressed in human HeLa cells co-transfected with Gal4-DBD assessed as transcriptional activation by Gal4 response element-driven luciferase reporter gene assay
    		[PMID: 19275963]
    Hepatocyte IC50
    165 μM
    Compound: Rosiglitazone
    Cytotoxicity against rat primary hepatocytes after 16 hrs
    Cytotoxicity against rat primary hepatocytes after 16 hrs
    		10.1039/C3MD00377A
    Hepatocyte IC50
    225 μM
    Compound: Rosiglitazone
    Cytotoxicity against rat primary hepatocytes after 6 hrs
    Cytotoxicity against rat primary hepatocytes after 6 hrs
    		10.1039/C3MD00377A
    HepG2 EC50
    > 10 μM
    Compound: Rosiglitazone
    Agonist activity at human PPAR alpha in HepG2 cells by PPAR-GAL4 transactivation assay
    Agonist activity at human PPAR alpha in HepG2 cells by PPAR-GAL4 transactivation assay
    		[PMID: 16979341]
    HepG2 EC50
    > 10 μM
    Compound: rosiglitazone
    Agonist activity at human PPAR alpha in a HepG2 cells by PPAR-GAL4 transactivation assay
    Agonist activity at human PPAR alpha in a HepG2 cells by PPAR-GAL4 transactivation assay
    		[PMID: 16973358]
    HepG2 EC50
    > 12 μM
    Compound: 3
    Agonist activity at human PPARalpha expressed in HepG2 cells by GAL4 transactivation assay
    Agonist activity at human PPARalpha expressed in HepG2 cells by GAL4 transactivation assay
    		[PMID: 19783444]
    HepG2 EC50
    > 12 μM
    Compound: 1, Rosi
    Agonist activity at human PPARalpha expressed in HepG2 cells by GAL4 transactivation assay
    Agonist activity at human PPARalpha expressed in HepG2 cells by GAL4 transactivation assay
    		[PMID: 18394907]
    HepG2 EC50
    0.002 μM
    Compound: Rosiglitazone
    Agonist activity at GAL4-fused PPARgamma M463A mutant (unknown origin) expressed in human HepG2 cells by transactivation assay
    Agonist activity at GAL4-fused PPARgamma M463A mutant (unknown origin) expressed in human HepG2 cells by transactivation assay
    		[PMID: 23502212]
    HepG2 EC50
    0.01 μM
    Compound: Rosiglitazone
    Agonist activity at GAL4-fused PPARgamma (unknown origin) expressed in human HepG2 cells by transactivation assay
    Agonist activity at GAL4-fused PPARgamma (unknown origin) expressed in human HepG2 cells by transactivation assay
    		[PMID: 23502212]
    HepG2 EC50
    0.02 μM
    Compound: Rosi
    Agonist activity at human GAL4-fused PPARgamma ligand binding domain expressed in HepG2 cells after 20 hrs by luciferase reporter gene transactivation assay
    Agonist activity at human GAL4-fused PPARgamma ligand binding domain expressed in HepG2 cells after 20 hrs by luciferase reporter gene transactivation assay
    		[PMID: 22081932]
    HepG2 EC50
    0.039 μM
    Compound: rosiglitazone
    Transactivation of GAL4-fused human PPARgamma ligand binding domain expressed in HepG2 cells after 20 hrs by luciferase reporter gene assay
    Transactivation of GAL4-fused human PPARgamma ligand binding domain expressed in HepG2 cells after 20 hrs by luciferase reporter gene assay
    		[PMID: 23171045]
    HepG2 EC50
    0.039 μM
    Compound: Rosiglitazone
    Agonist activity at human GAL4-PPARgamma ligand binding domain expressed in human HepG2 cells by luciferase reporter gene assay
    Agonist activity at human GAL4-PPARgamma ligand binding domain expressed in human HepG2 cells by luciferase reporter gene assay
    		[PMID: 25462281]
    HepG2 EC50
    0.039 μM
    Compound: rosiglitazone
    Agonist activity at GAL4-tagged human PPARgamma ligand binding domain expressed in human HepG2 cells assessed as receptor transactivation by luciferase reporter gene assay
    Agonist activity at GAL4-tagged human PPARgamma ligand binding domain expressed in human HepG2 cells assessed as receptor transactivation by luciferase reporter gene assay
    		[PMID: 19775169]
    HepG2 EC50
    0.039 μM
    Compound: Rosiglitazone
    Agonist activity at human PPARalpha ligand binding domain expressed in human HepG2 cells co-transfected with Gal4 by luciferase reporter gene assay
    Agonist activity at human PPARalpha ligand binding domain expressed in human HepG2 cells co-transfected with Gal4 by luciferase reporter gene assay
    		[PMID: 18835719]
    HepG2 EC50
    0.04 μM
    Compound: Rosiglitazone
    Agonist activity at GAL4-DNA binding domain fused human PPARgamma ligand binding domain expressed in human HepG2 cells assessed as receptor transactivation incubated for 20 hrs by luciferase reporter gene assay
    Agonist activity at GAL4-DNA binding domain fused human PPARgamma ligand binding domain expressed in human HepG2 cells assessed as receptor transactivation incubated for 20 hrs by luciferase reporter gene assay
    		[PMID: 25497132]
    HepG2 EC50
    0.04 μM
    Compound: Rosiglitazone
    Transactivation of GAL4-tagged human PPARgamma LBD expressed in human HepG2 cells at 100 nM to 100 uM incubated for 20 to 22 hrs by luciferase reporter gene assay
    Transactivation of GAL4-tagged human PPARgamma LBD expressed in human HepG2 cells at 100 nM to 100 uM incubated for 20 to 22 hrs by luciferase reporter gene assay
    		[PMID: 30996794]
    HepG2 EC50
    0.04 μM
    Compound: Rosiglitazone
    Agonist activity at human PPARgamma ligand binding domain expressed in human Hep G2 cells co-transfected with Gal4-DBD by luciferase reporter gene assay
    Agonist activity at human PPARgamma ligand binding domain expressed in human Hep G2 cells co-transfected with Gal4-DBD by luciferase reporter gene assay
    		[PMID: 19053776]
    HepG2 EC50
    0.043 μg/mL
    Compound: Rosiglitazone
    Activation of PPAR in human HepG2 cells after 24 hrs by luciferase reporter gene assay
    Activation of PPAR in human HepG2 cells after 24 hrs by luciferase reporter gene assay
    		[PMID: 22364952]
    HepG2 EC50
    0.05 μM
    Compound: Rosiglitazone
    Agonist activity at PPARgamma expressed in human HepG2 cells assessed as induction of receptor transactivation by reporter gene assay relative to control
    Agonist activity at PPARgamma expressed in human HepG2 cells assessed as induction of receptor transactivation by reporter gene assay relative to control
    		[PMID: 18625559]
    HepG2 EC50
    0.158 μM
    Compound: Rosiglitazone
    Agonist activity at human PPAR gamma in HepG2 cells by PPAR-GAL4 transactivation assay
    Agonist activity at human PPAR gamma in HepG2 cells by PPAR-GAL4 transactivation assay
    		[PMID: 16979341]
    HepG2 EC50
    0.158 μM
    Compound: rosiglitazone
    Agonist activity at human PPAR gamma in a HepG2 cells by PPAR-GAL4 transactivation assay
    Agonist activity at human PPAR gamma in a HepG2 cells by PPAR-GAL4 transactivation assay
    		[PMID: 16973358]
    HepG2 EC50
    0.223 μM
    Compound: 3
    Agonist activity at human PPARgamma expressed in HepG2 cells by GAL4 transactivation assay
    Agonist activity at human PPARgamma expressed in HepG2 cells by GAL4 transactivation assay
    		[PMID: 19783444]
    HepG2 EC50
    0.223 μM
    Compound: 1, Rosi
    Agonist activity at human PPARgamma expressed in HepG2 cells by GAL4 transactivation assay
    Agonist activity at human PPARgamma expressed in HepG2 cells by GAL4 transactivation assay
    		[PMID: 18394907]
    HepG2 EC50
    1.6 μM
    Compound: Rosiglitazone
    Transactivation of PPAR transfected in human HepG2 cells after 20 hrs by PPAR-luciferase assay
    Transactivation of PPAR transfected in human HepG2 cells after 20 hrs by PPAR-luciferase assay
    		[PMID: 25437304]
    HepG2 EC50
    10 nM
    Compound: Rosiglitazone
    Agonist activity at PPARgamma receptor expressed in human HepG2 cells by PPRE-luciferase reporter gene assay
    Agonist activity at PPARgamma receptor expressed in human HepG2 cells by PPRE-luciferase reporter gene assay
    		[PMID: 21482446]
    HepG2 EC50
    100 nM
    Compound: Rosiglitazone
    Transactivation of GAL4-fused PPARgamma ligand binding domain transfected in human HepG2 cells by luciferase reporter gene assay
    Transactivation of GAL4-fused PPARgamma ligand binding domain transfected in human HepG2 cells by luciferase reporter gene assay
    		[PMID: 22934537]
    HepG2 EC50
    50 nM
    Compound: Rosiglitazone
    Transactivation of human PPARgamma expressed in human HepG2 cells co-transfected with PPRE3-TK-Luc by luciferase reporter gene assay
    Transactivation of human PPARgamma expressed in human HepG2 cells co-transfected with PPRE3-TK-Luc by luciferase reporter gene assay
    		[PMID: 21450468]
    HepG2 EC50
    82 nM
    Compound: 1,rosiglitazone
    Agonist activity at human PPARgamma in HepG2 cells by PPAR-GAL4 transactivation assay
    Agonist activity at human PPARgamma in HepG2 cells by PPAR-GAL4 transactivation assay
    		[PMID: 17157019]
    Huh-7 EC50
    0.22 μM
    Compound: rosiglitazone
    Activity at human PPAR gamma in Huh7 cells by transactivation assay
    Activity at human PPAR gamma in Huh7 cells by transactivation assay
    		[PMID: 17034149]
    Huh-7 EC50
    0.22 μM
    Compound: 1
    Functional activity at human PPAR gamma in Huh7 cells by transactivation assay
    Functional activity at human PPAR gamma in Huh7 cells by transactivation assay
    		[PMID: 16366601]
    HUVEC IC50
    1.1 μM
    Compound: Rosiglitazone
    Anti-inflammatory activity in HUVEC assessed as reduction in TNFalpha-stimulated neutrophil-HUVEC interactions by measuring decrease in mononuclear leukocyte to endothelial cells pretreated for 20 hrs before TNFalpha stimulation for 24 hrs using freshly i
    Anti-inflammatory activity in HUVEC assessed as reduction in TNFalpha-stimulated neutrophil-HUVEC interactions by measuring decrease in mononuclear leukocyte to endothelial cells pretreated for 20 hrs before TNFalpha stimulation for 24 hrs using freshly i
    		[PMID: 31268307]
    L6 EC50
    4.49 μM
    Compound: Rosiglitazone
    Induction of glucose uptake in rat L6 cells pulsed with C14-deoxy glucose after 24 hrs in presence of insulin
    Induction of glucose uptake in rat L6 cells pulsed with C14-deoxy glucose after 24 hrs in presence of insulin
    		[PMID: 23992862]
    L6 IC50
    4.8 μM
    Compound: Rosi
    Increase in 2-[3H]-deoxyglucose uptake in rat L6 cells after 16 hrs by scintillation counting analysis
    Increase in 2-[3H]-deoxyglucose uptake in rat L6 cells after 16 hrs by scintillation counting analysis
    		[PMID: 24813738]
    MCF7 EC50
    87 nM
    Compound: rosiglitazone
    Agonist activity at human PPARgamma transfected in human MCF7 cells after 16 hrs by luciferase reporter gene assay
    Agonist activity at human PPARgamma transfected in human MCF7 cells after 16 hrs by luciferase reporter gene assay
    		[PMID: 26226490]
    MDA-MB-231 IC50
    5.23 μM
    Compound: Rosiglitazone
    Growth inhibition of human MDA-MB-231 cells after 24 hrs by MTT assay
    Growth inhibition of human MDA-MB-231 cells after 24 hrs by MTT assay
    		[PMID: 25278236]
    MG-63 EC50
    11 nM
    Compound: Rosiglitazone
    Modulation of full-length human pSG5-fused PPARgamma expressed in MG-63 cells co-expressing pGV-P2-PPRE after 24 hrs by luciferase reporter gene based transactivation assay
    Modulation of full-length human pSG5-fused PPARgamma expressed in MG-63 cells co-expressing pGV-P2-PPRE after 24 hrs by luciferase reporter gene based transactivation assay
    		[PMID: 22727448]
    MG-63 EC50
    11 nM
    Compound: Rosiglitazone
    Agonist activity at human PPARgamma expressed in MG-63 cells by reporter gene-based transactivation assay
    Agonist activity at human PPARgamma expressed in MG-63 cells by reporter gene-based transactivation assay
    		[PMID: 22225641]
    NIH3T3 EC50
    0.32 μM
    Compound: rosiglitazone
    Activity at human PPAR gamma transfected in NIH3T3 cells by luciferase activity assay
    Activity at human PPAR gamma transfected in NIH3T3 cells by luciferase activity assay
    		[PMID: 16854085]
    NIH3T3 EC50
    0.32 μM
    Compound: Rosiglitazone
    Agonist activity at human PPARgamma expressed in NIH3T3 cells by GAL4 transactivation assay
    Agonist activity at human PPARgamma expressed in NIH3T3 cells by GAL4 transactivation assay
    		[PMID: 17624777]
    PC-3 IC50
    20.3 μM
    Compound: Rosiglitazone
    Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 24996143]
    U2OS EC50
    0.01 M
    Compound: Rosiglitazone
    Agonist activity at human PPARgamma in human U2OS cells by cell based transactivation assay
    Agonist activity at human PPARgamma in human U2OS cells by cell based transactivation assay
    		[PMID: 19423341]
    U2OS EC50
    0.02 μM
    Compound: Rosiglitazone
    Agonist activity at human PPARgamma in U2OS cells by transactivation assay
    Agonist activity at human PPARgamma in U2OS cells by transactivation assay
    		[PMID: 18329751]
    U2OS EC50
    0.05 μM
    Compound: rosiglitazone
    Agonist activity at human PPARgamma expressed in U2OS cells by luciferase transactivation assay
    Agonist activity at human PPARgamma expressed in U2OS cells by luciferase transactivation assay
    		[PMID: 19574056]
    U2OS EC50
    259.42 nM
    Compound: ROS
    Transactivation of human PPARgamma transfected in U2OS cells co-tranfected with human RXR measured after 24 hrs by luciferase reporter assay
    Transactivation of human PPARgamma transfected in U2OS cells co-tranfected with human RXR measured after 24 hrs by luciferase reporter assay
    		[PMID: 31629632]
    U2OS IC50
    5.1 μM
    Compound: Rosiglitazone
    Inhibition of HA-tagged human NTCP expressed in human U2OS cells assessed as reduction in [14C]taurocholate uptake preincubated for 10 mins followed by [14C] taurocholate addition and further incubation for 10 mins by scintillation counting method
    Inhibition of HA-tagged human NTCP expressed in human U2OS cells assessed as reduction in [14C]taurocholate uptake preincubated for 10 mins followed by [14C] taurocholate addition and further incubation for 10 mins by scintillation counting method
    		[PMID: 31439379]
    體外研究
    (In Vitro)

    Rosiglitazone (0.1-10 μM，72 h) 導(dǎo)致多能 C3H10T1/2 干細(xì)胞分化為脂肪細(xì)胞[1]。
    Rosiglitazone (1 μM，24 h) 激活 PPARγ，后者與 NF-α1 啟動子激活神經(jīng)元中的基因轉(zhuǎn)錄[3]。
    Rosiglitazone (1 μM，24 小時) 保護(hù) Neuro2A 細(xì)胞和海馬神經(jīng)元免受氧化應(yīng)激，并上調(diào) BCL-2以 NF-α1 依賴性方式表達(dá)[3]。
    Rosiglitazone (0.01-100 μM，15 分鐘) 抑制 TRPM3，IC50 值為 9.5 和4.6 μM 分別抑制硝苯地平和 PregS 誘發(fā)的活性[4]。
    Rosiglitazone (0.5-50 μM，7 天) 抑制卵巢癌細(xì)胞增殖[7]。
    Rosiglitazone (5 μM，7 天) 抑制 Olaparib (HY-10162) 誘導(dǎo)的細(xì)胞衰老改變并促進(jìn) A2780 和 SKOV3 細(xì)胞凋亡[7]。

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Cell Proliferation Assay[7]

    Cell Line: A2780 and SKOV3 cells
    Concentration: 0.5-50 μM
    Incubation Time: 1-7 days
    Result: Inhibited cell proliferation in a time?dependent and concentration?dependent manner.

    Western Blot Analysis[3]

    Cell Line: Hippocampal neurons
    Concentration: 1 μM
    Incubation Time: 24 h
    Result: Increased NF-α1 and BCL-2 protein level.
    體內(nèi)研究
    (In Vivo)

    Rosiglitazone (口服給藥，5 mg/kg，每日一次，連續(xù) 8 周) 降低糖尿病大鼠的血糖[5]。
    Rosiglitazone (腹腔注射，3 mg/kg/天) 改善血糖香煙煙霧通過激活雄性 Wistar 大鼠 PPARγ 和 RXRα 抑制 M1 巨噬細(xì)胞極化引起的氣道炎癥[6]。
    Rosiglitazone (腹腔注射，10 mg/kg，每 2 天一次) 在 A2780 和 SKOV3 小鼠皮下異種移植模型中抑制皮下卵巢癌的生長[7]。

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Streptozotocin (STZ)-induced diabetic rats[5]
    Dosage: 5 mg/kg
    Administration: Oral administration, daily for 8 weeks.
    Result: Decreased IL-6, TNF-α, and VCAM-1 levels in diabetic group.
    Displayed lower levels of lipid peroxidation and NOx with an increase in aortic GSH and SOD levels compared to diabetic groups.
    Animal Model: Male Wistar rats[6]
    Dosage: 3 mg/kg/day
    Administration: Intraperitoneal injection, twice a day, 6 days per week for 12 consecutive weeks
    Result: Ameliorated emphysema, elevated PEF, and higher level of total cells, neutrophils and cytokines (TNF-α and IL-1β) induced by cigarette smoke (CS).
    Inhibited CS-induced M1 macrophage polarization and decreased the ratio of M1/M2.
    Clinical Trial
    分子量

    357.43

    Formula

    C18H19N3O3S
    CAS 號
    性狀

    固體

    顏色

    White to off-white

    中文名稱

    羅格列酮
    運輸條件

    Room temperature in continental US; may vary elsewhere.
    儲存方式
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 6 months
    -20°C 1 month
    溶解性數(shù)據(jù)
    細(xì)胞實驗： 

    DMSO 中的溶解度 : 175 mg/mL (489.61 mM; 超聲助溶; 吸濕的 DMSO 對產(chǎn)品的溶解度有顯著影響，請使用新開封的 DMSO)

    Ethanol 中的溶解度 : 2 mg/mL (5.60 mM; 超聲助溶 (<60°C))

    H2O 中的溶解度 : < 0.1 mg/mL (insoluble)

    配制儲備液
    濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg
    1 mM 2.7978 mL 13.9888 mL 27.9775 mL
    5 mM 0.5596 mL 2.7978 mL 5.5955 mL
    查看完整儲備液配制表

    * 請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；一旦配成溶液，請分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
    儲備液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C儲存時，請在6個月內(nèi)使用，-20°C儲存時，請在1個月內(nèi)使用。

    • 摩爾計算器

    • 稀釋計算器

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    質(zhì)量
    =
    濃度
    ×
    體積
    ×
    分子量 *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    濃度 (start)

    C1

    ×
    體積 (start)

    V1

    =
    濃度 (final)

    C2

    ×
    體積 (final)

    V2

    動物實驗：

    請根據(jù)您的 實驗動物和給藥方式 選擇適當(dāng)?shù)娜芙夥桨浮?

    以下溶解方案都請先按照 In Vitro 方式配制澄清的儲備液，再依次添加助溶劑：
    ——為保證實驗結(jié)果的可靠性，澄清的儲備液可以根據(jù)儲存條件，適當(dāng)保存；體內(nèi)實驗的工作液，建議您現(xiàn)用現(xiàn)配，當(dāng)天使用；
    以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶

    • 方案 一

      請依序添加每種溶劑： 10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 5 mg/mL (13.99 mM); 澄清溶液

      此方案可獲得 ≥ 5 mg/mL（飽和度未知）的澄清溶液。

      以 1 mL 工作液為例，取 100 μL 50.0 mg/mL 的澄清 DMSO 儲備液加到 400 μL PEG300 中，混合均勻；再向上述體系中加入 50 μL Tween-80，混合均勻；然后再繼續(xù)加入 450 μL 生理鹽水 定容至 1 mL。

      生理鹽水的配制：將 0.9 g 氯化鈉，溶解于 ddH?O 并定容至 100 mL，可以得到澄清透明的生理鹽水溶液。
    • 方案 二

      請依序添加每種溶劑： 10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 5 mg/mL (13.99 mM); 澄清溶液

      此方案可獲得 ≥ 5 mg/mL（飽和度未知）的澄清溶液。

      以 1 mL 工作液為例，取 100 μL 50.0 mg/mL 的澄清 DMSO 儲備液加到 900 μL 20% 的 SBE-β-CD 生理鹽水水溶液 中，混合均勻。

      2 g SBE-β-CD（磺丁基醚 β-環(huán)糊精）粉末定容于 10 mL 的生理鹽水中，完全溶解至澄清透明。

    以下溶解方案，請直接配制工作液。建議現(xiàn)用現(xiàn)配，在短期內(nèi)盡快用完。 以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比； 如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶。

    • 方案 一

      請依序添加每種溶劑： 0.5% CMC-Na/saline water

      Solubility: 10 mg/mL (27.98 mM); 懸濁液; 超聲助溶

    動物溶解方案計算器
    請輸入動物實驗的基本信息：

    給藥劑量

    mg/kg

    動物的平均體重

    g

    每只動物的給藥體積

    μL

    動物數(shù)量

    只
    由于實驗過程有損耗，建議您多配一只動物的量
    請輸入您的動物體內(nèi)配方組成：
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    如果您的動物是免疫缺陷鼠或者體弱鼠，建議 DMSO 中的在最后工作液體系中的占比盡量不超過 2%。
    方案所需 助溶劑 包括：DMSO， ，均可在 MCE 網(wǎng)站選購。 ，Tween 80，均可在 MCE 網(wǎng)站選購。
    計算結(jié)果
    工作液所需濃度 : mg/mL
    儲備液配制方法 : mg 藥物溶于 μL  DMSO（母液濃度為 mg/mL）。
    您所需的儲備液濃度超過該產(chǎn)品的實測溶解度，以下方案僅供參考，如有需要，請與 MCE 中國技術(shù)支持聯(lián)系。
    動物實驗體內(nèi)工作液的配制方法 : 取 μL DMSO 儲備液，加入 μL 。 μL ，混合均勻至澄清，再加 μL Tween 80，混合均勻至澄清，再加 μL 生理鹽水。
    連續(xù)給藥周期超過半月以上，請謹(jǐn)慎選擇該方案。
    請確保第一步儲備液溶解至澄清狀態(tài)，從左到右依次添加助溶劑。您可采用超聲加熱 （超聲清洗儀，建議頻次 20-40 kHz），渦旋吹打等方式輔助溶解。
    純度 & 產(chǎn)品資料

    純度: 99.94%

    參考文獻(xiàn)

    完整儲備液配制表

    * 請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；一旦配成溶液，請分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
    儲備液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C儲存時，請在6個月內(nèi)使用，-20°C儲存時，請在1個月內(nèi)使用。

    可選溶劑 濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg 25 mg
    Ethanol / DMSO 1 mM 2.7978 mL 13.9888 mL 27.9775 mL 69.9438 mL
    5 mM 0.5596 mL 2.7978 mL 5.5955 mL 13.9888 mL
    DMSO 10 mM 0.2798 mL 1.3989 mL 2.7978 mL 6.9944 mL
    15 mM 0.1865 mL 0.9326 mL 1.8652 mL 4.6629 mL
    20 mM 0.1399 mL 0.6994 mL 1.3989 mL 3.4972 mL
    25 mM 0.1119 mL 0.5596 mL 1.1191 mL 2.7978 mL
    30 mM 0.0933 mL 0.4663 mL 0.9326 mL 2.3315 mL
    40 mM 0.0699 mL 0.3497 mL 0.6994 mL 1.7486 mL
    50 mM 0.0560 mL 0.2798 mL 0.5596 mL 1.3989 mL
    60 mM 0.0466 mL 0.2331 mL 0.4663 mL 1.1657 mL
    80 mM 0.0350 mL 0.1749 mL 0.3497 mL 0.8743 mL
    100 mM 0.0280 mL 0.1399 mL 0.2798 mL 0.6994 mL
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    您最近查看的產(chǎn)品:

    Your information is safe with us. * Required Fields.

       產(chǎn)品名稱：

    		  

    * 需求量：

    * 客戶姓名：

    		 

    * Email：

    * 電話：

    		 

    * 公司或機構(gòu)名稱：

       留言給我們：

    Bulk Inquiry

    Inquiry Information

    產(chǎn)品名稱：
    Rosiglitazone
    目錄號：
    HY-17386
    需求量：